Dyax, Lee's Pharmaceutical deal

Dyax granted Lee's CVie Therapeutics subsidiary exclusive rights to develop and commercialize Kalbitor ecallantide to treat hereditary angioedema (HAE) and other angioedema indications in China. Dyax will receive an upfront payment and is eligible for milestones and royalties. CVie will also purchase the drug from Dyax. Dyax said Kalbitor has not been tested in clinical trials in China and that CVie plans to meet with regulatory officials to discuss a path for the drug. Dyax declined to provide details, while CVie could not be reached...